Samuel Martel1, Elena Poletto2, Arlindo R Ferreira3, Matteo Lambertini4, Federico Sottotetti5, Ilaria Bertolini6, Filippo Montemurro7, Antonio Bernardo5, Emanuela Risi8, Elisa Zanardi9, Serena Ziliani10, Silvia Mura11, Chiara Dellepiane12, Lucia Del Mastro12, Alessandro Marco Minisini2, Fabio Puglisi13. 1. Département d'Hémato-Oncologie, CISSS Montérégie Centre/Hôpital Charles-Lemoyne, Centre Affilié de l'Université de Sherbrooke, Greenfield Park, Qc, Canada; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. 2. Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. 3. Hospital de Santa Maria and Instituto de Medicina Molecular, Faculdade de Leducuba, Universidade de Lisboa, Lisbon, Portugal. 4. Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: matteo.lambertini85@gmail.com. 5. Medical Oncology, Istituti Clinici Scientifici Maugeri IRCCS, Via Salvatore Maugeri, 8-10, 27100, Pavia, Italy. 6. UO Oncologia 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Via Roma 67, 56126, Pisa, Italy. 7. Investigative Clinical Oncology (INCO), FPO-Candiolo Cancer Institute (IRCSS), Strada Provinciale 142, 10060, Candiolo, Italy. 8. Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Azienda USL Toscana Centro, Via Suor Niccolina Infermiera 20, 59100, Prato, Italy. 9. Department of Medical Oncology, Clinica di Oncologia Medica, Ospedale Policlinico San Martino-IST, Largo Rosanna Benzi 10, 16132, Genova, Italy. 10. Department of Medical Oncology, San Paolo Hospital, Savona, Italy. 11. Department of Medical Oncology, AOU Ospedale Santissima Annunziata, Via Enrico de Nicola, Sassari, Italy. 12. Department of Medical Oncology, U.O. Sviluppo Terapie Innovative, Ospedale Policlinico San Martino-IST, Largo Rosanna Benzi 10, 16132, Genova, Italy. 13. Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy; Department of Clinical Oncology, CRO Aviano National Cancer Institute, Aviano, Italy.
Abstract
BACKGROUND: Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). METHODS: This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was collected. World Health Organization BMI categories were used: underweight <18.5, normal 18.5-24.9 Kg/m2, overweight 25-29.9 Kg/m2, and obese ≥30 Kg/m2. The analyses were conducted using two categories: BMI < 25.0 (normal/underweight) and BMI ≥ 25 (overweight/obese). Progression-free survival (PFS) and overall survival (OS) rates were estimated using Kaplan-Meier method. Univariate and multivariate survival analyses were performed using the Cox's proportional hazards model. Disease response to therapy was analyzed using univariate and multivariate logistic regression. RESULTS: Overall, 176 (53.5%) patients were normal/underweight and 153 (46.5%) overweight/obese. Median PFS was 14.8 months in BMI < 25 group and 15.7 months in BMI ≥ 25 group (adjusted-HR 0.88; 95% CI 0.66-1.17; p = 0.387). Median OS was 58.6 months in BMI < 25 group and 52.6 in BMI ≥ 25 group (adjusted-HR 0.88; 95% CI 0.59-1.31; p = 0.525). Overall response rate was 71.7% and 65.9% (p = 0.296) and clinical benefit rate was 82.1% and 83.3% (p = 0.781) in BMI < 25 and BMI ≥ 25 groups, respectively. CONCLUSIONS: BMI does not seem to be associated with clinical outcomes in HER2-positive MBC patients.
BACKGROUND: Overweight and obesity are associated with an increased risk of developing many types of cancer, including breast cancer. Moreover, increased body mass index (BMI) seems to be associated with a worse prognosis in patients with HER2-positive early breast cancer. However, little is known about the impact of BMI on the clinical outcomes of HER2-positive metastatic breast cancer (MBC). METHODS: This was a multicenter retrospective cohort study including 329 consecutive patients with HER2-positive MBC treated with first-line trastuzumab-based regimens. BMI at the time of MBC diagnosis was collected. World Health Organization BMI categories were used: underweight <18.5, normal 18.5-24.9 Kg/m2, overweight 25-29.9 Kg/m2, and obese ≥30 Kg/m2. The analyses were conducted using two categories: BMI < 25.0 (normal/underweight) and BMI ≥ 25 (overweight/obese). Progression-free survival (PFS) and overall survival (OS) rates were estimated using Kaplan-Meier method. Univariate and multivariate survival analyses were performed using the Cox's proportional hazards model. Disease response to therapy was analyzed using univariate and multivariate logistic regression. RESULTS: Overall, 176 (53.5%) patients were normal/underweight and 153 (46.5%) overweight/obese. Median PFS was 14.8 months in BMI < 25 group and 15.7 months in BMI ≥ 25 group (adjusted-HR 0.88; 95% CI 0.66-1.17; p = 0.387). Median OS was 58.6 months in BMI < 25 group and 52.6 in BMI ≥ 25 group (adjusted-HR 0.88; 95% CI 0.59-1.31; p = 0.525). Overall response rate was 71.7% and 65.9% (p = 0.296) and clinical benefit rate was 82.1% and 83.3% (p = 0.781) in BMI < 25 and BMI ≥ 25 groups, respectively. CONCLUSIONS: BMI does not seem to be associated with clinical outcomes in HER2-positive MBCpatients.
Authors: Charles N Birts; Constantinos Savva; Stéphanie A Laversin; Alicia Lefas; Jamie Krishnan; Aron Schapira; Margaret Ashton-Key; Max Crispin; Peter W M Johnson; Jeremy P Blaydes; Ellen Copson; Ramsey I Cutress; Stephen A Beers Journal: Sci Rep Date: 2022-05-24 Impact factor: 4.996
Authors: Maria Alice Franzoi; Daniel Eiger; Lieveke Ameye; Noam Ponde; Rafael Caparica; Claudia De Angelis; Mariana Brandão; Christine Desmedt; Serena Di Cosimo; Nuria Kotecki; Matteo Lambertini; Ahmad Awada; Martine Piccart; Evandro de Azambuja Journal: J Natl Cancer Inst Date: 2021-04-06 Impact factor: 13.506
Authors: Marco Gallo; Valerio Adinolfi; Viola Barucca; Natalie Prinzi; Valerio Renzelli; Luigi Barrea; Paola Di Giacinto; Rosaria Maddalena Ruggeri; Franz Sesti; Emanuela Arvat; Roberto Baldelli; Emanuela Arvat; Annamaria Colao; Andrea Isidori; Andrea Lenzi; Roberto Baldell; M Albertelli; D Attala; A Bianchi; A Di Sarno; T Feola; G Mazziotti; A Nervo; C Pozza; G Puliani; P Razzore; S Ramponi; S Ricciardi; L Rizza; F Rota; E Sbardella; M C Zatelli Journal: Rev Endocr Metab Disord Date: 2020-10-06 Impact factor: 6.514
Authors: Jennifer A Ligibel; Luke Huebner; Hope S Rugo; Harold J Burstein; Debra L Toppmeyer; Carey K Anders; Cynthia Ma; William T Barry; Vera Suman; Lisa A Carey; Ann H Partridge; Clifford A Hudis; Eric P Winer Journal: JNCI Cancer Spectr Date: 2021-04-12
Authors: Natansh D Modi; Jin Quan Eugene Tan; Andrew Rowland; Bogda Koczwara; Ahmad Y Abuhelwa; Ganessan Kichenadasse; Ross A McKinnon; Michael D Wiese; Michael J Sorich; Ashley M Hopkins Journal: NPJ Breast Cancer Date: 2021-03-22